KNOWLEDGE BANK

Interviews

ExpreS2ion Biotechnologies

Vice President - Business Development
ExpreSion Biotechnologies protein expression system ExpreS is an important protein expression tool in the scientists tool box for protein expression The ExpreS platform has demonstrated in many instances its usefulness in RD with several ExpreSmade proteins having now been crystallized

Articles

The Rapidly Evolving Landscape of Cancer Therapeutics

Cancer is considered as a common name to address a large group comprising more than diseases affecting several parts of the body All cancers show common characteristics such as the uncontrolled growth and proliferation of abnormal cells

Research Insights

A network medicine approach to investigation and population-based validation of disease manifestations and drug repurposing for COVID-19

The global coronavirus disease COVID pandemic caused by severe acute respiratory syndrome coronavirus SARSCoV has led to unprecedented social and economic consequences The risk of morbidity and mortality due to COVID increases dramatically in the presence of coexisting medical conditions

Case Studies

Solid Form Changes During Drug Development: Good, Bad, And Ugly Case Studies

The relevance of solid form in drug development has been well established over time In order to fully understand drug properties attention has been paid to solid state structure of drug molecules and their relationship to the drug formulation While each drug developer has had their own strategies and workflows for screening and choosing solid forms of drug molecules t...

Techno Trends

Auvelity™, Novel Treatment Discovered for the Treatment of Depressive Disorder

Axsome Therapeutics Inc discovers novel AUVELITYTM dextromethorphan HBr bupropion HCl extended release tablets for the treatment of major depressive disorders in adults It is the novel oral NMDA receptor antagonist consisting of multimodal activity approved for the treatment of MDD in adults

White Papers

Cloud Computing in the Laboratory Informatics Solutions and Validation Approaches

In the modern business environment, a significant portion of work is conducted using computerized systems. Many solutions are used to complete tasks, including simple desktop programs like email and Microsoft Office to enterprise-wide, global systems like ERP (Enterprise Resource Planning), MES (Manufacturing Execution System), and LIMS

TOP ARTICLES

1

New Paradigm in Combination Therapy of siRNA with Chemotherapeutic Drugs towards Cancer Targeting

Ruchi Chawla

Ruchi is currently designated as Associate Professor, Department of Pharmaceutical Engineering & Technology, Indian Institute of Technology (Banaras Hindu University), Varanasi-221005, (U.P.), India. Her area of research is nanotechnology based drug delivery systems for targeted delivery of drugs and addressing issues related to conventional dosage forms like poor bioavailability, solubility, higher dose. She has more than 20 publications in international scientific journals including original research articles, reviews and book chapters. e-mail ID – rchawla.phe@iitbhu.ac.in

 

Krishan Kumar

Krishan Kumar is currently pursuing Ph.D. in Pharmaceutics at Department of Pharmaceutical Engineering, IIT BHU. His research focus on targeted and controlled drug delivery approaches in Nano-therapeutics. He has authored or co-authored 8 publications in international scientific journals in his fields of expertise. He has 2 years 8 months R&D experience in Reckitt Benckiser (India) Ltd. e-mail ID- krishaniskrishan@gmail.com

 

Varsha Rani

Varsha Rani is currently Ph.D. research scholar at Department of Pharmaceutical Engineering and Technology, IIT (BHU) Varanasi, India. She is involved in research area focussed on nanocarriers for brain targeted drug delivery system. She has contributed to ten publications including research article, review article and book chapter in reputed scientific journals. She has also done industrial training from Evonik India Pvt. Ltd, Mumbai, India. e-mail ID – varsharani.rs.phe17@itbhu.ac.in

 

Mohini Mishra

Mohini Mishra is a PhD research scholar at Indian Institute of Technology BHU, Varanasi, India and his area of research is focused on the development of nanoparticulate-based targeted drug delivery systems against BHneurodegenerative diseases. She has authored and co- authored nine publications in international scientific journals and three are in the pipeline. e-mail ID- mohini.mishra0203@gmail.com

 

2

Changing Paradigms in Use of AI in Chemical Sciences

Prashant S. Kharkar

Prashant S. Kharkar, a well-respected Drug Discovery Researcher with rich industrial experience, received his B. Pharm. degree in 1998. He obtained his PG and Ph.D. (Tech.) degrees Institute of Chemical Technology (ICT), Mumbai, India. Dr. Kharkar completed his postdoctoral research (2006–2009) on neurodegenerative diseases and disorders.

Akash S. Sirsat

Akash Sirsat is pursuing M.Tech in Pharmaceutical Chemistry and Technology at the Institute of Chemical Technology (ICT), Mumbai. He completed his Bachelor of Pharmacy from Sinhgad Institute’s SKNCOP, Pune. His research interests include pharmaceutical chemistry, process development, and applications of AI/ML in pharmaceutical synthesis. He has qualified GPAT, GATE, NIPER, and GAT-B.

3

Are We Ready to Ship Billions of COVID Vaccines Worldwide?

Kawal Preet

President, Asia Pacific, Middle East and Africa, FedEx Express

4

Natural Polymers and Fibers in Drug Delivery

Dr. Meghraj V. Suryawanshi

Dr. Meghraj V. Suryawanshi is an Associate Professor and Co-Founder of Sandip Institute of Pharmaceutical Sciences. He holds M.Pharm, MBA, PDCR, and Ph.D. degrees. With over 7 years of research experience and 4 years in teaching, his expertise lies in polymer science, novel drug delivery systems (NDDS), and intellectual property rights (IPR). Dr. Suryawanshi has authored more than 55 publications, 8 books, and holds several patents. He actively leads innovative pharmaceutical research with a strong focus on translational impact.

Akshata Yashwant Patne

Akshata Yashwant Patne is a pharmaceutical nanotechnology expert with over 3 years of experience in clinical research, drug delivery, and AI-driven therapeutics. She has led nanoparticle-based studies, published peer-reviewed articles, and actively mentors students, combining science, innovation, and leadership across academia, research, and global scientific communities.

5

How the Pharmaceutical Industry is Embracing a Technology-Driven Approach to Unlock New Growth Avenues

Nikkhil K Masurkar

Nikkhil K Masurkar, a research pharmacist with a dynamic entrepreneurial streak. Nikkhil K Masurkar is executive director of the ENTOD International Group - a leading specialty research-based pharma company specialising in ophthalmic, ENT and Dermatology medicines. As a third generation entrepreneur, Nikkhil took over his family’s three decade old pharmaceutical business. However, to ensure he was adequately prepared to lead the organisation into the 21st century, he delved deep into clinical pharmacy and pharmacy research for several years prior to it. He is a highly qualified research pharmacist from Kings College London (UK) with various clinical pharmacy and formulation research accreditations to his name. He also studied clinical pharmacy in Belfast and is also a member of the prestigious Royal Pharmaceutical Society in the UK. His strong leadership qualities, dynamic entrepreneurial spirit and sharp business acumen together with impressive pharmaceutical and research skills have enabled ENTOD to become one of the fastest growing speciality pharmaceutical companies in India and abroad.

 

press releasesRead more...

Waters Launches AI Link, Advancing AI-Enabled LC-MS Workflows from Research to Release

Waters Corporation announced that it has launched Waters AI Link a software capability that brings Anthropics Model Context Protocol MCP to its informatics platform and has joined Anthropics Model Hardware Standard MHS research program

Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1

Takeda announced that ORZEYFUL oveporexton is now available in Japan and China for the treatment of narcolepsy type NT providing first access to clinicians to prescribe treatment with the new class of medicine ORZEYFUL is a firstinclass orexin receptor OXR agonist in tablet form designed to treat...

Merck Inaugurates State-of-the-Art ADVANCE Bioanalytical Facility on West Point, Pennsylvania, Campus

Merck known as MSD outside of the United States and Canada today inaugurated its stateoftheart ADVANCE research facility on its West Point Pennsylvania campus signaling a new chapter in global scientific discovery Pennsylvania Gov Josh Shapiro joined Merck executive leadership federal and state gove...

Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg

Alvotech a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited a global pharmaceutical company with a strategic focus on specialty hospital and rare disease medicines today announced the submissi...

Rhythm Pharmaceuticals Announces Commercial Launch of IMCIVREE® (setmelanotide) in Japan for Patients with Acquired Hypothalamic Obesity

Rhythm Pharmaceuticals Inc a global commercialstage biopharmaceutical company focused on transforming the lives of patients living with rare neuroendocrine diseases today announced the commercial launch of IMCIVREE setmelanotide in Japan to treat patients living with acquired hypothalamic obesity HO...

Scinai Expands CDMO Business with $5.1 Million Development and Clinical Manufacturing Agreement

Scinai Immunotherapeutics Ltd a biopharmaceutical company operating a growing contract development and manufacturing organization CDMO alongside an immunologyfocused therapeutic development platform today announced that its wholly owned subsidiary Scinai Biopharma Services Ltd has entered into a def...

EventsRead more...

21 - 23

Oct 2026

21 - 22

Oct 2026

22 - 23

Oct 2026

PDA Aseptic Symposium 2026

Congress Square Nakanoshima, O...

26 - 28

Oct 2026

ACHEMA Middle East 2026

RICEC, Riyadh, KSA, Saudi Arab...

26 - 28

Oct 2026

World Orphan Drug Congress

RAI, Amsterdam, Netherlands

27 - 28

Oct 2026

PM& AC 2026

Novotel Hyderabad Convention C...

28 - 30

Oct 2026

02 - 04

Nov 2026

Pharma Forum EMEA 2026

Dom Pedro Lisboa Hotel, Lisbon...

LATEST NEWSRead more...

Nxera Pharma Partners with Synmosa to Commercialise QUVIVIQ

Nxera Pharma has entered into an exclusive licensing supply and commercialisation agreement with Synmosa Biopharma to expand access to QUVIVIQ daridorexant a medicine used to treat insomnia across eight AsiaPacific markets QUVIVIQ was discovered and developed by Idorsia Pharmaceuticals

Vir Biotechnology Enters into Collaboration with Gilead Sciences to Develop T-cell Engagers for Solid Tumours

Vir Biotechnology has entered into a collaboration and licensing agreement with Gilead Sciences to discover and develop three novel Tcell engager TCE candidates for the treatment of solid tumours Tcell engagers are designed to direct T cells a type of immune cell towards cancer cells and help destro...

Zealand Pharma Enters into Collaboration with Generate Biomedicines on AI-Designed Protein Therapies for Metabolic Diseases

Zealand Pharma and Generate Biomedicines have entered into a multitarget collaboration and licensing agreement to develop proteinbased treatments for obesity and other metabolic diseases using artificial intelligence AI The collaboration will combine Zealand Pharmas expertise in metabolic diseases w...

Enodia Therapeutics Enters into Collaboration with Pfizer to Develop Small-Molecule Sec61 Inhibitors

Enodia Therapeutics has entered into a research collaboration and licensing agreement with Pfizer to discover and develop smallmolecule inhibitors targeting Sec a protein complex involved in the movement of newly formed proteins across cell membranes

InnoCare Announces Approval of Clinical Trial of Bispecific Antibody ICP-B161 Targeting TL1A and IL-23p19 in China

InnoCare Pharma a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases announced today that the Center for Drug Evaluation CDE of Chinas National Medical Products Administration NMPA has approved its Investigational New Drug IND application for ICPB a bispeci...

Mint Pharmaceuticals and Bayer Expand Medicine Distribution in Canada

Mint Pharmaceuticals and Bayer have expanded their distribution partnership in Canada to include several additional medicines across womens health cardiovascular care and anticoagulation